Evidence map›Paper›PMID 31630355›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2020

Cross-talk between ribosome biogenesis, translation, and mTOR in CD133+ 4/CD44+ prostate cancer stem cells.

Z Binal, E Açıkgöz, F Kızılay, G Öktem, B Altay

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Z BinalDepartment of Urology, Faculty of Medicine, Ege University School of Medicine, Ege University, Bornova, PO Box: 35100, 35100, İzmir, Turkey.
E AçıkgözDepartment of Histology and Embryology, Faculty of Medicine, Yuzuncu Yıl University, 65080, Van, Turkey.
F KızılayDepartment of Urology, Faculty of Medicine, Ege University School of Medicine, Ege University, Bornova, PO Box: 35100, 35100, İzmir, Turkey. fuatkizilay@gmail.com.ORCID http://orcid.org/0000-0003-1856-0404
G ÖktemDepartment of Histology and Embryology, Faculty of Medicine, Ege University, 35100, Izmir, Turkey.
B AltayDepartment of Urology, Faculty of Medicine, Ege University School of Medicine, Ege University, Bornova, PO Box: 35100, 35100, İzmir, Turkey.
Ege University · TRVan Yüzüncü Yıl Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the gene expression profile of CSCs and to explore the key pathways and specific molecular signatures involved in the characteristic of CSCs. MATERIALS AND

methodsCD133+ /CD44+ CSCs and bulk population (non-CSCs) were isolated from DU-145 cells using fluorescence-activated cell sorting (FACS). We used Illumina HumanHT-12 v4 Expression to investigate gene expression profiling of CSCs and non-CSCs. Protein-protein interaction (PPI) network analysis was performed using the STRING database. Biomarkers selected based on gene expression profiling were visually analyzed using immunofluorescence staining method. An image analysis program, ImageJ®, was used for the analysis of fluorescence intensity.

resultsIn microarray analysis, we found that many ribosomal proteins and translation initiation factors that constitute the mTOR complex were highly expressed. PPI analysis using the 33 genes demonstrated that there was a close interaction between ribosome biogenesis, translation, and mTOR signaling. The fluorescence amount of mTOR and MLST8 were higher in CSCs compared to non-CSCs.

conclusionsThe increase in a number of genes associated with ribosome biogenesis, translation, and mTOR signaling may be important to evaluate prognosis and determine treatment approach for prostate cancer (PCa). A better understanding of the molecular pathways associated with CSCs may be promising to develop targeted therapies to prolong survival in PCa.

Indexed as

Organelle BiogenesisTranscriptomeAC133 AntigenCell Line, TumorEukaryotic Initiation FactorsFlow CytometryHumansHyaluronan ReceptorsMalemTOR Associated Protein, LST8 HomologNeoplastic Stem CellsProstatic NeoplasmsProtein Interaction MapsRibosomal ProteinsRibosomesSpheroids, CellularAC133 AntigenEukaryotic Initiation FactorsHyaluronan ReceptorsMLST8 protein, humanmTOR Associated Protein, LST8 HomologMTOR protein, humanRibosomal ProteinsTOR Serine-Threonine KinasesCancer stem cellmTORProstate cancerRibosomal proteinsTranslation

Identifiers

PMID31630355
OpenAlexW2980601380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.